SEATTLE, WA--(Marketwired - Jan 5, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual Biotech Showcase Conference on January 9, 2017 at 5:00pm PST, Ballroom 7, at the Hilton San Francisco Union Square Hotel, San Francisco, CA. Management will also be available for one-on-one meetings on January 9 and 10, 2017.
Registered attendees may request meetings by contact the conference at https://ebdgroup.knect365.com/biotech-showcase/
About Atossa Genetics
Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.